Zynex Inc

Zynex Inc. is a U.S.-based medical device company headquartered in Englewood, Colorado, focused on electrotherapy and pain management products. Through its operating subsidiaries, it sells and leases devices and supplies used in home and clinical settings, and it also owns a patient-monitoring technology platform developed through its ZMS subsidiary.

4,6 %

79,5 %

1,6 %

+4,4 %

4.46

3.63

— Zynex Inc
	%
Electrotherapy devices	45% Pain-management and rehabilitation devices sold or leased to patients and providers.
Supplies	45% Recurring consumables used with electrotherapy products, mainly electrodes and batteries.
Private-labeled rehabilitation products	5% Branded support and therapy products sold alongside the core device portfolio.
Patient monitoring technologies	5% Laser-based noninvasive monitoring products under development through ZMS/Kestrel.

Zynex sells primarily into the U.S. healthcare market, with reimbursement-driven demand from patients using...

Home-use pain management patientsprimary
Patients who receive electrotherapy devices and recurring supplies for chronic pain or rehabilitation.
Healthcare payers and insurersprimary
Third-party payers that determine reimbursement levels and claim acceptance for device and supply revenue.
Physicians and prescribing clinicssecondary
Clinicians that drive patient placement by recommending Zynex devices and related supplies.
Strategic commercialization partnersemerging
Potential partners for NiCO and HemeOx who could help bring monitoring technologies to market.

Zynex is headquartered in Englewood, Colorado and conducts most of its operations through U.S.-based subsidiaries...

•Headquartered in Englewood, Colorado
•Most operations run through U.S. subsidiaries ZMI and ZMS
•Core revenue is tied to the U.S. healthcare reimbursement system
•Inactive subsidiaries include Zynex Europe and other legacy entities
•Trade policy and import exposure can affect sourced components

Zynex’s core strategy centers on selling and supporting electrotherapy devices and recurring supplies through its U.S...

Grow core electrotherapy and supply franchiseshort-term

Recurring supplies and device placements are the main commercial engine of the business.

Increase sales force productivityshort-term

The company depends on efficient patient acquisition and prescription conversion.

Partnerize monitoring technologiesmedium-term

Strategic partners may provide regulatory, commercial, and funding support for NiCO and HemeOx.

Zynex is exposed to reimbursement, payer, and claim-processing risk because a large part of its revenue depends on...

high

Third-party payer reimbursement disruption

Revenue depends on insurer payment decisions, claim processing, and patient eligibility.

Scope: Core device and supply revenue
Materiality: high

high

Strategic partnership execution risk

NiCO and HemeOx may require external partners to reach market and generate value.

Scope: Monitoring technology pipeline
Materiality: high

medium

Tariffs and import cost inflation

Manufactured products and components sourced outside the U.S. may become more expensive.

Scope: Cost of revenue and gross margin
Materiality: medium

medium

Regulatory and litigation risk

SEC requests and other legal matters can create expense, uncertainty, and reputational damage.

Scope: Corporate and operating risk
Materiality: medium

Revenue recognition net of payer deductions

Can materially change net revenue and receivables

Allowance for uncollectible accounts

Affects revenue, accounts receivable, and cash conversion

Goodwill and intangible impairment

Can create large non-cash charges

Income tax valuation allowance and discrete items

Affects effective tax rate and net income

Zynex Inc

Third-party payer reimbursement disruption

Strategic partnership execution risk

Tariffs and import cost inflation

Regulatory and litigation risk

Zymeworks Inc.

Zicix Corp

ZyVersa Therapeutics, Inc.

Neuraxis, INC

PULSE BIOSCIENCES, INC.

Streamex Corp.